Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

Compass Pathways’ depression drug trial meets goals but falls short of investor hopes, triggering a sharp share selloff.

Illinois health officials continue to regularly report COVID deaths. The CDC reports Illinois had 11 weekly COVID deaths ...